South Korean AI company Lunit has partnered with Mexican medical network Salud Digna to distribute its AI-based imaging analysis software to more than 230 clinical sites across Mexico and Central America.
The deal covers Lunit’s INSIGHT MMG for mammography diagnostics and analysis and INSIGHT CXR, a software for chest X-ray analysis that recently demonstrated superior performance in tuberculosis (TB) detection in an independent study.
In the study, published in The Lancet Digital Health, INSIGHT CXR achieved the highest accuracy out of 12 tested AI-based TB detection products. The software displayed 89.9% sensitivity at 67.7% specificity, and an 89.5% sensitivity at 70.2% specificity, meeting the World Health Organization’s (WHO) target product profile.
Lunit said the partnership means Salud Digna’s network clinicians will gain the ability to conduct faster, more accurate imaging analysis while enabling access to Salud Digna’s extensive database of deidentified medical images, which it will utilise to refine AI algorithms specifically tailored to the Latin American market.
In addition, Lunit stated that, unlike typical partnerships of this nature, it will also work with Salud Digna on research projects aimed at the further development of medical imaging AI to improve healthcare delivery across the region.
Salud Digna CEO Juan Carlos Ordoñez said: "By integrating Lunit's advanced AI into our healthcare network, we aim to improve the accuracy and efficiency of our imaging services.
"Together, we are committed to leveraging our extensive data resources to drive innovation in medical imaging and ultimately improve patient care across the region."
In 2022, Lunit obtained a CE mark under the EU’s revised Medical Device Regulation (MDR) and a UK Conformity Assessed (UKCA) marking for Lunit INSIGHT, its suite of AI solutions for radiology, becoming the first software as a medical device (SaMD) company in the Asia Pacific region to do so.
GlobalData’s 2023 AI in Healthcare report forecasts that AI platforms across healthcare will reach a global valuation of $18.8bn by 2027.
